Tetanus Toxoid Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Tetanus Toxoid Vaccine Market is segmented By Vaccine Type (Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, And Pertussis (Tdap), Other Vaccines), By End User and Geography.

Tetanus Toxoid Vaccine Market Snapshot

Tetanus Toxoid Vaccine Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Tetanus Toxoid Vaccine Market is expected to register a CAGR of 4.8% during the forecast period. Tetanus also known as lockjaw is a non-communicable serious disease caused by a bacterial toxin that affects the nervous system, leading to painful muscle contractions, particularly jaw and neck muscles. It is caused by Clostridium tetani (C tetani) which is found in human and animal feces, soil and street dust. The bacteria enter the body through wounds. Some of the symptoms include lockjaws (paralysis of the jaw), muscle stiffness, back pain, difficulties in breathing and spasms. Most of all cases of tetanus occur in people who have never been vaccinated or in adults who haven't kept up with their 10-year booster shots. There are different vaccines that include protection against tetanus are DTaP vaccine, DT vaccine, Tdap vaccine and Td vaccine.

According to the World Health Organization (WHO) in 2015 worldwide, about 34,000 newborns died from neonatal tetanus. In addition, there were 15,103 reported cases of tetanus and diphtheria in 2018 with an increase from 13,500 tetanus cases in 2016. As the number of cases have increased in recent years the market is expected to grow in coming years.

Rising cases of tetanus and diphtheria, new products under the clinical trials and increasing government initiatives regarding vaccination and immunization are the key driving factors of tetanus toxoid vaccine market.

Scope of the Report

As per the scope of the report, Tetanus is an acute infectious disease caused by spores of the bacterium Clostridium tetani. These spores are found in soil, intestinal tracts or feces of animals and human, surfaces of skin and rusty tools like nails. Tetanus Toxoid Vaccine Market is segmented By Vaccine Type, End user and Geography.

By Vaccine Type
Diphtheria, Tetanus, and Pertussis (DTaP)
Diphtheria and Tetanus (DT)
Tetanus, Diphtheria, And Pertussis (Tdap)
Other Vaccines
By End User
Hospitals and Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccines Segment is Expected to Hold a Major Market Share in the Tetanus Toxoid Vaccine Market

  • Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment holds a significant market share in the tetanus toxoid vaccine market and is anticipated to show a similar trend over the forecast period owing to growing government initiatives to eradicate these diseases.
  • DTaP is a vaccine that helps in developing immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis) in children younger than 7 years old.
  • According to the World Health Organization (WHO), in 2017 worldwide 38,000 people died from tetanus. Around half (49%) were younger than five years old. Moreover, 77% of all deaths from tetanus, 29,500 lives lost, occur in South Asia and Sub-Saharan Africa. In addition, South Asia and Sub-Saharan Africa account for 82% of all tetanus cases globally.
  • Low costs of the vaccine, increasing cases of tetanus and increasing availability in low resource economies like Africa are the key driving factors in the Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment.
Tetanus toxoid vaccine  market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global tetanus toxoid vaccine market due to increasing cases of tetanus and diphtheria, and higher cost, high coverage, and adoption in this region. According to the Centers for Disease Control and Prevention (CDC), in 2017, a total of 33 tetanus cases and 2 deaths were reported in the United States. Moreover, from 2009 through 2017, a total of 264 cases and 19 deaths from tetanus were reported. Sixty cases (23%) were in people with 65 years of age or older, 168 cases (64%) in people 20 to 64 years of age, and 36 cases (13%) were in younger than 20 years. All tetanus-related deaths occurred among patients greater than 55 years of age. Furthermore, increasing focus to control the incidence and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Tetanus Toxoid Vaccine Market

Competitive Landscape

The Tetanus Toxoid Vaccine Market is fragmented competitive and consists of a several major players. Some of the prominent players which are currently dominating the market are Merck & Co. Inc, GlaxoSmithKline Plc, Sanofi (Sanofi Pasteur, Inc), Pfizer, Inc, Bharat Biotech, Astellas Pharma Inc, Panacea Biotec Ltd, BB - NCIPD Ltd, PT Bio Farma and Biological E Limited.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Cases of Tetanus and Diphtheria

      2. 4.2.2 Growing Research and Development Activities for New Vaccines

      3. 4.2.3 Increasing Government Initiatives Programs for Vaccination

    3. 4.3 Market Restraints

      1. 4.3.1 Side-Effects Associated with Toxoid Vaccine

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Vaccine Type

      1. 5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)

      2. 5.1.2 Diphtheria and Tetanus (DT)

      3. 5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)

      4. 5.1.4 Other Vaccines

    2. 5.2 By End User

      1. 5.2.1 Hospitals and Clinics

      2. 5.2.2 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co. Inc

      2. 6.1.2 GlaxoSmithKline Plc

      3. 6.1.3 Sanofi (Sanofi Pasteur, Inc)

      4. 6.1.4 Pfizer, Inc

      5. 6.1.5 Bharat Biotech

      6. 6.1.6 Astellas Pharma Inc

      7. 6.1.7 Panacea Biotec Ltd

      8. 6.1.8 BB - NCIPD Ltd

      9. 6.1.9 PT Bio Farma

      10. 6.1.10 Biological E Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Tetanus Toxoid Vaccine Market market is studied from 2018 - 2026.

The Tetanus Toxoid Vaccine Market is growing at a CAGR of 4.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck & Co. Inc, GlaxoSmithKline Plc, Sanofi (Sanofi Pasteur, Inc), Pfizer, Inc, Bharat Biotech are the major companies operating in Tetanus Toxoid Vaccine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!